Department of Population Health, NYU Grossman School of Medicine, United States of America.
Columbia University Department of Psychiatry, New York State Psychiatric Institute, United States of America.
J Subst Abuse Treat. 2021 Jul;126:108329. doi: 10.1016/j.jsat.2021.108329. Epub 2021 Feb 18.
Maintenance treatments with medications for opioid use disorder (MOUD) are highly effective at reducing overdose risk while patients remain in care. However, few patients initiate medication and retention remains a critical challenge across settings. Much remains to be learned about individual and structural factors that influence successful retention, especially among populations dispensed MOUD in outpatient settings.
We examined individual and structural characteristics associated with MOUD treatment retention among a national sample of adults seeking MOUD treatment in outpatient substance use treatment settings using the 2017 Treatment Episode Dataset-Discharges (TEDS-D). The study assessed predictors of retention in MOUD using multivariate logistic regression and accelerated time failure models.
Of 130,300 episodes of MOUD treatment in outpatient settings, 36% involved a duration of care greater than six months. The strongest risk factors for treatment discontinuation by six months included being of younger age, ages 18-29 ((OR):0.52 [95%CI:0.50-0.54]) or 30-39 (OR:0.57 [95%CI:0.55-0.59); experiencing homelessness (OR: 0.70 [95%CI:0.66-0.73]); co-using methamphetamine (OR:0.48 [95%CI:0.45-0.51]); and being referred to treatment by a criminal justice source (OR:0.55 [95%CI:0.52-0.59) or by a school, employer, or community source (OR:0.71 [95%CI:0.66-0.76).
Improving retention in treatment is a pivotal stage in the OUD cascade of care and is critical to reducing overdose deaths. Efforts should prioritize interventions to improve retention among patients who are both prescribed and dispended MOUD, especially youth, people experiencing homelessness, polysubstance users, and people referred to care by the justice system who have especially short stays in care.
维持治疗用药物治疗阿片类药物使用障碍(MOUD)在患者接受治疗期间,非常有效地降低了过量风险。然而,很少有患者开始接受药物治疗,保留仍然是所有环境中的一个关键挑战。还有很多关于影响成功保留的个人和结构因素需要了解,尤其是在门诊环境中接受 MOUD 治疗的人群中。
我们使用 2017 年治疗发作数据集-出院(TEDS-D),检查了全国寻求门诊药物使用治疗的成年人 MOUD 治疗保留的个人和结构特征。研究使用多变量逻辑回归和加速时间失败模型评估了 MOUD 治疗保留的预测因素。
在 130300 例门诊 MOUD 治疗发作中,36%的治疗持续时间超过六个月。治疗中断的最强风险因素包括年龄较小,年龄在 18-29 岁(OR:0.52[95%CI:0.50-0.54])或 30-39 岁(OR:0.57[95%CI:0.55-0.59);无家可归(OR:0.70[95%CI:0.66-0.73);同时使用冰毒(OR:0.48[95%CI:0.45-0.51);以及由刑事司法来源(OR:0.55[95%CI:0.52-0.59)或由学校、雇主或社区来源(OR:0.71[95%CI:0.66-0.76)转介治疗。
提高治疗保留率是 OUD 护理级联中的一个关键阶段,对于减少过量死亡至关重要。努力应优先考虑干预措施,以提高处方和分配 MOUD 的患者的保留率,特别是年轻人、无家可归者、多药使用者以及被司法系统转介到护理的人,他们在护理中的停留时间特别短。